United States: FDA's Office Of Prescription Drug Promotion Issues Second Untitled Letter Of The Year To Exeltis For Misleading Statements Relating To SLYND® - Sheppard Mullin Richter & Hampton
On August 11, 2023, the Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) issued an untitled letter to Exeltis USA Inc. (Exeltis) regarding a promotional...
Full Article